97 results on '"Usmani, Saad Z"'
Search Results
2. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
3. Cost per Responder Analysis of Patients with Lenalidomide-Refractory Multiple Myeloma Who Received Cilta-Cel from the Cartitude-4 Trial
4. Biomarker Correlates of 3 Year Response in Cartitude-1: A Phase 1b/2 Open-Label Study of Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma
5. Real World Outcomes of Older Adults and Frail Patients with Relapse/Refractory Multiple Myeloma Receiving Idecabtagene Vicleucel
6. Acquired Immunity in Patients with Multiple Myeloma Undergoing Maintenance Therapy Post-Autologous Hematopoietic Cell Transplantation
7. SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM
8. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
9. MO50-4 Efficacy and safety of commercially approved BCMA-targeting CAR-T therapy in triple-class refractory multiple myeloma
10. Overcoming Barriers to Autologous Stem Cell Transplantation in Multiple Myeloma: Recommendations from a Multidisciplinary Roundtable Discussion
11. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
12. POSTER: MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study
13. MM-455 Adjusted Indirect Treatment Comparison of Progression-Free Survival Associated With D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
14. Progression-Free Survival of Daratumumab vs. Bortezomib Triplet Combination with Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study
15. POSTER: MM-455 Adjusted Indirect Treatment Comparison of Progression-Free Survival Associated With D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
16. MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study
17. POSTER: MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study
18. MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study
19. How Old is Too Old for CAR-T Cell Therapies in Multiple Myeloma?
20. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma
21. A clinical and correlative study of elotuzumab, carfilzomib, lenalidomide and dexamethasone (Elo-KRd) for lenalidomide refractory multiple myeloma in first relapse
22. Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study
23. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients
24. Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study
25. Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma
26. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study
27. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials
28. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
29. MM-181 CARTITUDE-1: Two-Year Post Last Patient in (LPI) Results From the Phase 1b/2 Study of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
30. Poster: MM-181 CARTITUDE-1: Two-Year Post Last Patient in (LPI) Results From the Phase 1b/2 Study of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
31. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
32. Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma
33. Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
34. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
35. Post-protocol therapy and informative censoring in the CANDOR study – Authors' reply
36. Results from a Meta-Analysis of Ciltacabtagene Autoleucel Compared to Physician’s Choice in Patients with Relapsed or Refractory Multiple Myeloma
37. Cartitude-5: A Randomized, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Intended for Transplant
38. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
39. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
40. P-204: Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Kd: subgroup analysis of the CANDOR study by prior autologous stem cell transplantation, Lenalidomide exposure, or Lenalidomide refractory disease
41. P-201: Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma
42. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
43. OAB-002: Daratumumab improves depth of response and progression free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma (NDMM)
44. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma
45. OAB-024: Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM)
46. OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study
47. Novel BCMA Targeted ADCs, Bispecific and Trispecific Antibodies
48. Poster: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
49. Oral Abstract: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
50. MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.